BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: de Bruijn RE, Nijkamp J, Noe A, Horenblas S, Haanen JB, Prevoo W, Bex A. Baseline tumor volume in assessing prognosis of patients with intermediate-risk synchronous metastatic renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations 2016;34:258.e7-258.e13. [DOI: 10.1016/j.urolonc.2015.12.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
Number Citing Articles
1 Blute ML, Ziemlewicz TJ, Lang JM, Kyriakopoulos C, Jarrard DF, Downs TM, Grimes M, Shi F, Mann MA, Abel EJ. Metastatic Tumor Burden Does Not Predict Overall Survival Following Cytoreductive Nephrectomy for Renal Cell Carcinoma: a Novel 3-Dimensional Volumetric Analysis. Urology 2017;100:139-44. [DOI: 10.1016/j.urology.2016.09.016] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
2 Larcher A, Wallis CJ, Bex A, Blute ML, Ficarra V, Mejean A, Karam JA, Van Poppel H, Pal SK. Individualised Indications for Cytoreductive Nephrectomy: Which Criteria Define the Optimal Candidates? European Urology Oncology 2019;2:365-78. [DOI: 10.1016/j.euo.2019.04.007] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 8.7] [Reference Citation Analysis]
3 Esagian SM, Ziogas IA, Kosmidis D, Hossain MD, Tannir NM, Msaouel P. Long-Term Survival Outcomes of Cytoreductive Nephrectomy Combined with Targeted Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Individual Patient Data Meta-Analysis. Cancers (Basel) 2021;13:695. [PMID: 33572149 DOI: 10.3390/cancers13040695] [Reference Citation Analysis]
4 Silagy AW, Duzgol C, Marcon J, DiNatale RG, Mano R, Blum KA, Reznik E, Voss MH, Motzer RJ, Coleman JA, Russo P, Akin O, Hakimi AA. An evaluation of the role of tumor load in cytoreductive nephrectomy. Can Urol Assoc J 2020;14:E625-30. [PMID: 32569570 DOI: 10.5489/cuaj.6350] [Reference Citation Analysis]
5 Cao C, Shou J, Shi H, Jiang W, Kang X, Xie R, Shang B, Bi X, Zhang J, Zheng S, Zhou A, Li C, Ma J. Novel cut-off values of time from diagnosis to systematic therapy predict the overall survival and the efficacy of targeted therapy in renal cell carcinoma: A long-term, follow-up, retrospective study. Int J Urol 2021. [PMID: 34847622 DOI: 10.1111/iju.14751] [Reference Citation Analysis]